Figure 3.

(A) Effects of IDA (0.05-0.5 μM) on the viability of U937 cells. The growth suppressive effect of IDA on U937 cells was assessed using MTT assay. IC₅₀ pharmaceutical dose for U937 cells was 0.2 µM. (B) Data indicated that the anti-proliferative effects of IDA was attenuated in the presence of different AML-derived EVs. (C) When U937 cells were treated with relapsed AML-EVs (30 µg) in combination with IDA, there was a more significant elevation in the IC₅₀ value of IDA. Data are mean ± SE of three independent experiments. Statistical significance was defined at ^*P < 0.05, ^**P < 0.01 and ^***P < 0.001 compared to corresponding control